Christer Ahlberg | BiotechTV

top of page

Swiss Nordic Bio 2026: Cinclus Pharma has a key phase 3 scheduled to read out in Q4 on its next-generation potassium-competitive acid blocker (PCAB) in patients with erosive GERD

President & CEO Christer Ahlberg sets the table for this key event. Coverage brought to you by

Company News

3 hours ago

Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to usher in the next generation of acid reflux medicines with linaprazan glurate, a potassium-competitive acid blocker (P-CAB)

CEO Christer Ahlberg describes the shortcomings of today's medicines, and why he believes a P-CAB is the answer. This therapy originated...

Company News

Sep 16, 2025

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

Learn more

bottom of page

Swiss Nordic Bio 2026: Cinclus Pharma has a key phase 3 scheduled to read out in Q4 on its next-generation potassium-competitive acid blocker (PCAB) in patients with erosive GERD

Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to usher in the next generation of acid reflux medicines with linaprazan glurate, a potassium-competitive acid blocker (P-CAB)

Follow BiotechTV

Sponsors

Sponsor Spotlight